Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene?

Abstract

Mutation analysis methods have increased in variety during the past years. High-throughput microarray methods have especially increased in popularity. However, new methods require reference points, and not all of the methods are equal in sensitivity and specificity. Furthermore, the detection of unknown missense mutations, such as unknown TP53 mutations in human tumors, for clinical purposes requires great accuracy, which may be difficult to acquire with the current high-throughput methods. For these reasons, the classical methods, such as PCR-manual sequencing and PCR-SSCP, are still valuable and necessary.

Keywords

comparison of methods mutation analysis optimisation significance of TP53 mutations

References

Hollstein M , Sidransky B , Vogelstein C , Harris CC. P53 mutations in human cancers . Science 1991; 253: 49-53 .

Greenblatt MS , Bennett WP , Hollstein M , Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res 1994; 54: 4855-4878 .

Hainaut P , Soussi T , Shomer B , Hollstein M et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects . Nucleic Acid Res 1997; 25: 151-157 .

Vähäkangas KH. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. In Driscoll B ed. Lung cancer; Volume 1: Molecular pathology methods and reviews, methods in molecular medicine. Humana Press , 2002: 43-59.

Bennett WP , Hussain SP , Vähäkangas KH , Khan MA et al. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer . J Pathol 1999; 187: 8-18 .

Hainaut P , Hollstein M. P53 and human cancer: the first ten thousand mutations . Adv Cancer Res 2000; 77: 81-137 .

Sigal A , Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome . Cancer Res 2000; 60: 6788-6793 .

Van Oijen MGCT , Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53 . Clin Cancer Res 2000; 6: 2138-2145 .

Guimaraes DP , Hainaut P. TP53: a key gene in human cancer . Biochimie 2002; 84: 83-93 .

10.

Varley JM , Evans DGR , Birch JM. Li-Fraumeni syndrome - a molecular and clinical review . Br J Cancer 1997; 76: 1-14 .

11.

Chompret A. The Li-Fraumeni syndrome . Biochimie 2002; 84: 75-82 .

12.

Bougeard G , Brugieres L , Chompret A , Gesta P et al. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene . Oncogene 2003; 22: 840-846 .

13.

Staib F , Hussain SP , Hofseth LJ , Wang XW et al. TP53 and liver carcinogenesis . Hum Mutat 2003; 21: 201-216 .

14.

Szymanska K , Hainaut P. TP53 and mutations in human cancer . Acta Biochim Pol 2003; 50: 231-238 .

15.

Vähäkangas K. TP53 mutations in workers exposed to occupational carcinogens . Hum Mutat 2003; 21: 240-251 .

16.

Harris CC. The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene . Br J Cancer 1996; 73: 261-269 .

17.

Lane DP , Lain S. Therapeutic exploitation of the p53 pathway . Trends Mol Med 2002; 8: 38-42 .

18.

Lane DP , Hupp TR. Drug discovery and p53 . Drug Discov Today 2003; 8: 347-355 .

19.

Seemann S , Maurici D , Olivier M , de Fromentel CC et al. The tumor suppressor gene TP53: implications for cancer management and therapy . Crit Rev Clin Lab Sci 2004; 41: 551-583 .

20.

Pfeifer GP , Hainaut P. On the origin of G0/T transversions in lung cancer . Mutat Res 2003; 526: 39-43 .

21.

Hainaut P , Pfeifer GP. Patterns of p53 G0/T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke . Carcinogenesis 2001; 22: 367-374 .

22.

Hainaut P , Vähäkangas K. P53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations . Pathol-Biol 1997; 45: 833-844 .

23.

Borresen A-L , Andersen TI , Eyfjord JE , Cornelis RS et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains . Genes Chromos Cancer 1995; 14: 71-75 .

24.

Valgardsdottir R , Tryggvadottir L , Steinarsdottir M , Olafsdottir K et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis . Acta Pathol Microbiol Immunol Scand 1997; 105: 121-130 .

25.

Bull SB , Ozcelik H , Pinnaduwage D , Blackstein ME et al. The combination of p53 mutation and neu/arbB- 2 amplification is associated with poor survival in node-negative breast cancer . J Clin Oncol 2004; 22: 86-96 .

26.

Huang C , Taki T , Adachi M , Konishi T et al. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer . Oncogene 1998; 16: 2469-2477 .

27.

Ahrendt SA , Hu Y , Buta M , McDermott MP et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study . J Natl Cancer Inst 2003; 95: 961-970 .

28.

Bradford CR , Chu S , Poore J , Fisher SG et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma . Arch Otolaryngol - Head Neck Surg 1997; 123: 605-660 .

29.

Alsner J , Sorensen SB , Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but no surgery, in squamous cell carcinoma of the head and neck . Radiother Oncol 2001; 59: 179-185 .

30.

Bandoh N , Hayashi T , Kishibe K , Takahara M et al. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma . Cancer 2002; 94: 1968-1980 .

31.

Anker P , Lyautey J , Lederrey C , Stroun M. Circulating nucleic acids in plasma or serum . Clin Chim Acta 2000; 313: 143-146 .

32.

Gonzalez R , Silva JM , Sanchez Dominguez G , Garcia JM et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance . Ann Oncol 2000; 11: 1097-1104 .

33.

Wang JY , Hsieh JS , Chang MY , Huang TJ et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers . World J Surg 2004; 28: 721-726 .

34.

Andriani F , Conte D , Mastrangelo T , Leon M et al. Detecting lung cancer in plasma with the use of multiple genetic markers . Int J Cancer 2004; 108: 91-96 .

35.

Cabelguenne A , Blons H , de Waziers I , Carnot F et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series . J Clin Oncol 2000; 18: 1465-1473 .

36.

Jiang T , Minunni M , Mascini M. Towards fast and inexpensive molecular diagnostic: the case of TP53 . Clin Chim Acta 2004; 343: 45-60 .

37.

Bertheau, Plassa F , Espie M , Turpin E et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy . Lancet 2002; 360: 852-854 .

38.

Bradford CR , Zhu S , Ogawa H , Ogawa Ubell M et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma cell lines . Head Neck 2003; 25: 654-661 .

39.

Andrews GA , Xi S , Pomerantz RG , Lin CJ et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis . Head Neck 2004; 26: 870-877 .

40.

Bauer JA , Trask DK , Kumar B , Los G et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL . Mol Cancer Ther 2005; 4: 1096-1104 .

41.

Vogelstein B , Lane D , Levine AJ. Surfing the p53 network . Nature 2000; 408: 307-310 .

42.

Chan WM , Siu WY , Lau A , Poon RYC.

How many mutant p53 molecules are needed to inactivate a tetramer?

Mol Cell Biol 2004; 24: 3536-3551 .

43.

Vähäkangas KH , Samet JM , Metcalf RA , Welsh JA et al. Mutations of the p53 and ras genes in radon-associated lung cancer from uranium miners . Lancet 1992; 339: 576-580 .

44.

Williams C , Ponten F , Moberg C , Soderkvist P et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens . Am J Pathol 1999; 155: 1467-1471 .

45.

Vähäkangas KH , Bennett WP , Castren K , Welsh JA et al. p53 and K-ras mutations in lung cancers from former and never-smoking women . Cancer Res 2001; 61: 4350-4356 .

46.

Anami Y , Takeuchi T , Mase K , Yasuda J et al. Amplotyping of microdissected, methanol-fixed lung carcinoma by arbitrarily primed polymerase chain reaction . Int J Cancer 2000; 89: 19-25 .

47.

Teixeira MR , Pandis N , Heim S. Cytogenetic clues to breast carcinogenesis . Genes Chromosome Cancer 2002; 33: 1-16 .

48.

Welsh JA , Castren K , Vähäkangas K. Single-strand conformation polymorphism analysis to detect p53 mutations: characterization and development of controls . Clin Chem 1997; 43: 2251-2255 .

49.

Vähäkangas KH , Castren K , Welsh JA. Single-strand conformation polymorphism analysis of mutations in exons 4-8 of the TP53 gene. In Killeen AA ed. Methods in molecular medicine; Volume 49: molecular pathology protocols. Humana Press Inc. 2000: 15-27 (invited paper).

50.

Linderholm B , Norberg T , Bergh J. Sequencing of the tumor suppressor gene TP53 . Methods Mol Med 2006; 120: 389-401 .

51.

Nollau P , Wagener C. Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques . Clin Chem 1997; 43: 1114-1128 .

52.

Blaszyc K , Hartmann A , Schroeder JJ , McGovern RM et al. Rapid and efficient screening for p53 gene mutations by dideoxy fingerprinting . Biotechniques 1995; 18: 256-260 .

53.

Tennis M , Krishnan S , Bonner M , Ambrosone CB et al. p53 mutation analysis in breast tumors by a DNA microarray method . Cancer Epidemiol Biomark Prev 2006; 15: 80-85 .

54.

Fischer SG , Lerman LS. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory . Proc Natl Acad Sci USA 1983; 80: 1579-1583 .

55.

Sheffield VC , Cox DR , Lerman LS , Myers RM. Attachment of a 40-base-pair G+C-rich sequence (GC-lamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes . Proc Natl Acad Sci USA 1989; 86: 232-236 .

56.

Condie A , Eeles R , Borresen AL , Coles C et al. Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydro-xylamine and osmium tetroxide techniques . Hum Mutat 1993; 2: 58-66 .

57.

Guldberg P , Nedergaard T , Nilesen HJ , Olsen AC et al. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer . Hum Mutat 1997; 9: 348-355 .

58.

Garcia-Delgado M , Gonzalez-Navarro CJ , Napal MC , Baldonado C et al. Higher sensitivity of denaturing gradient gel electrophoresis than sequencing in the detection of mutations in DNA from tumor samples . Biotechniques 1998; 24(1): 72-76 .

59.

Ferretti G , Curigliano G , Pastorino U , Cittadini A et al. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from respectable non-small cell lung cancer . Clin Cancer Res 2000; 6: 2393-2400 .

60.

McGrath SB , Bounpheng M , Torres L , Calavetta M et al. High-speed, multicolor fluorescent two-dimensional gene scanning . Genomics 2001; 78: 83-90 .

61.

Dhanda RK , van Orsouw NJ , Sigalas I , Eng C et al. Critical factors in the performance and cost of two-dimensional gene scanning: RB1 as a model . Biotechniques 1998; 25: 664-668, 670-670, 672-675 .

62.

Rines RD , van Orsouw NJ , Sigalas I , Li FP et al. Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning . Carcinogenesis 1998; 19: 979-984 .

63.

Frueh FW , Noyer-Weidner M. The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics . Clin Chem Lab Med 2003; 41: 452-461 .

64.

Lu C , Xu HM , Ren Q , Ao Y et al. Somatic mutation analysis of p53 and ST7 tumor suppressor genes in gastric carcinoma by DHPLC . World J Gastroenterol 2003; 9: 2662-2665 .

65.

Jansson A , Gentile M , Sun X-F. p53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation . Int J Cancer 2001; 92: 338-341 .

66.

Castren K , Ranki A , Welsh J , Vähäkangas K. Infrequent p53 mutations in arsenic-related skin lesions . Oncol Res 1998; 10: 475-482 .

67.

Ryu J-W , Lee M-C , Jang W-C. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining . J Korean Med Sci 2000; 15: 73-77 .

68.

Hall PA , Lane DP.

p53 in tumor pathology: can we trust immunohistochemistry?

J Pathol 1994; 172: 1-4 .

69.

Lu M-L , Wikman F , Orntoft TF , Charytonowicz E et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods . Clin Cancer Res 2002; 8: 171-179 .

70.

Curtin K , Slattery ML , Holubkov R , Edwards S et al. P53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry . Appl Immunohistochem Mol Morphol 2004; 12: 380-386 .

71.

Hall PA , McKee PH , Menage HD , Dover R , Lane DP. High levels of p53 protein in UV-irradiated normal human skin . Oncogene 1993; 8: 203-207 .

72.

Turpeinen M , Serpi R , Rahkolin M , Vähäkangas K. Comparison of anti-p53 antibodies in immunoblotting . Biochem Biophys Res Commun 2002; 293: 850-856 .

73.

Taubert H , Wurl P , Bache M , Meye A et al. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry . Anticancer Res 1998; 18: 183-188 .

74.

Flaman JM , Frebourg T , Moreau V , Charbonnier F et al. A simple p53 functional assay for screening cell lines, blood and tumors . Proc Natl Acad Sci USA 1995; 92: 3963-3967 .

75.

Tada M , Iggo RD , Waridel F , Nozaki M et al. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses . Mol Carcinogen 1997; 18: 171-176 .

76.

Fronza G , Inga A , Monti P , Scott G et al. The yeast p53 functional assay: a new tool for molecular epidemiology . Hopes and facts. Mutat Res 2000; 462: 293-301 .

77.

Orita M , Iwahana H , Kanazawa H , Hayashi K et al. Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms . Proc Natl Acad Sci USA 1989; 86: 2766-2770 .

78.

Hayashi K. PCR-SSCP: a method for detection of mutations . GATA 1992; 9: 73-92 .

79.

Makino R , Kaneko K , Kurahashi T , Matsumura T et al. Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and automated DNA sequencer in a large number of DNA samples . Mutat Res 2000; 452: 83-90 .

80.

Hongyo T , Buzard GS , Calvert RJ , Weghorst CM. ‘Cold SSCP’: a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses . Nucl Acid Res 1993; 21: 3637-3642 .

81.

Iwahana H , Yoshimoto K , Mizusawa N , Kudo E et al. Multiple fluorescence-based PCR-SSCP analysis . Biotechniques 1994; 16: 296-297 .

82.

Inazuka M , Wenz HM , Sakabe M , Tahira T et al. A streamlined mutation detection system: multicolor post-PCR fluorescence labeling and single-strand conformational analysis by capillary electrophoresis . Genome Res 1997; 7: 1094-1103 .

83.

Kourkine IV , Hestekin CN , Barron AE. Technical challenges in applying capillary electrophoresis-single strand conformation polymorphism for routine genetic analysis . Electrophoresis 2002; 23: 1375-1385 .

84.

Ellison J , Dean M , Goldman D. Efficacy of fluorescence-based PCR-SSCP for detection of point mutations . BioTechniques 1993; 15: 684-691 .

85.

Glavac D , Dean M. Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations . Hum Mutat 1993; 2: 404-414 .

86.

Hakkarainen J , Welsh JA , Vähäkangas KH. TP53 mutation detection by SSCP and sequencing. In Roulston JE , Bartlett JMS eds. Methods in molecular medicine; Volume 97: molecular diagnosis of cancer. Humana Inc. , 2003: 187-203.

87.

Hayashi K , Yandell DW.

How sensitive is PCR-SSCP?

Hum Mutat 1993; 2: 338-346 .

88.

Moyret C , Theillet C , Puig PL , Moles JP et al. Relative efficiency of denaturing gradient gel electrophoresis and single-strand conformation polymorphism in the detection of mutations in exon 5 to 8 of the p53 gene . Oncogene 1994; 9: 1739-1743 .

89.

Lehman TA , Bennett WP , Metcalf RA , Welsh JA et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines . Cancer Res 1991; 51: 4090-4096 .

90.

Tullo A , Sbisa` E. Molecular characterization of p53 mutations in primary and secondary liver tumors . Mol Biotechnol 2002; 21: 265-278 .

91.

Sheffield VC , Beck JS , Kwitek AE , Sandstrom DW et al. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions . Genomics 1993; 16: 325-332 .

92.

Bosari S , Marchetti A , Buttitta F , Graziani D et al. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis . Diagn Mol Pathol 1995; 4: 249-255 .

93.

Kaserer K , Schmaus J , Bethge U , Migschitz B et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer . J Pathol 2000; 190: 450-456 .

94.

Kashiwazaki H , Tonoki H , Tada M , Chiba I et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay . Oncogene 1997; 15: 2667-2674 .

95.

Meinhold-Heerlein I , Ninci E , Igenberg H , Brandstetter T et al. Evaluation of methods to detect p53 mutations in ovarian cancer . Oncology 2001; 60: 176-188 .

96.

Orita M , Suzuki Y , Sekiya T , Hayashi K. DNA sequence polymorphisms in Alu repeats . Genomics 1990; 8: 271-278 .

97.

Pinheiro NA , Moura RP , Monteiro E , Villa LL. Detection of point mutations by non-isotopic single strand conformation polymorphism . Braz J Med Biol Res 1999; 32: 55-58 .

98.

Suzuki Y , Orita M , Shiraishi M , Hayashi K et al. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products . Oncogene 1990; 5: 1037-1043 .

99.

Wang Y , Yamaguchi Y , Watanabe H , Ohtsubo K et al. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of tract carcinoma: comparison with K-ras mutation . J Gastroenterol 2002; 37: 831-839 .

100.

Kurvinen K , Hietanen S , Syrjänen K , Syrjänen S. Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™ . J Virol Methods 1995; 51: 43-54 .

101.

Peng H , Du M , Ji J , Isaacson PG et al. High-resolution SSCP analysis using polyacrylamide agarose composite gel and a background-free silver staining method . Biotechniques 1995; 19: 410-414 .

102.

Behn M , Schuermann M. Sensitive detection of p53 gene mutations by a ‘mutant enriched’ PCR-SSCP technique . Nucleic Acid Res 1998; 26: 1356-1358 .

103.

Conway K , Edmiston SN , Cui L , Drouin SS et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer . Cancer Res 2002; 62: 1987-1995 .

104.

Chaubert P , Beautista D , Benhattar J. An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformational polymorphism procedure . Biotechniques 1993; 15: 586-586 .

105.

Cheng J , Haas M. Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing . PCR Methods Appl 1992; 1: 199-201 .

106.

Worsham MJ , Pals G , Raju U , Wolman SR. Establishing a molecular continuum in breast cancer: DNA microarrays and benign breast disease . Cytometry 2002; 47: 56-59 .

107.

Wu JK , Ye Z , Darras BT. Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumours with mixed cell populations . Am J Hum Genet 1993; 52: 1273-1275 .

108.

Wen WH , Reles A , Runnebaum IB , Sullivan-Halley J et al. p53 mutations and expression in ovarian cancers: correlation with overall survival . Int J Gynecol Pathol 1999; 18: 29-41 .

109.

Sood AK , Sorosky JI , Dolan M , Anderson B et al. Distant metastases in ovarian cancer: association with p53 mutations . Clin Cancer Res 1999; 5: 2485-2490 .

110.

Reles A , Wen WH , Schmider A , Gee C et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer . Clin Cancer Res 2001; 7: 2984-2997 .

111.

Taubert H , Meye A , Würl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients . Cancer Res 1996; 56: 4134-4136 .

112.

Berg C , Hedrum A , Holmberg A , Ponten F et al. Direct solid-phase sequence analysis of the human p53 gene by use of multiplex polymerase chain reaction and a-thiophosphate nucleotides . Clin Chem 1995; 41: 1461-1466 .

113.

Swisher EM , Wollan M , Mahtani SM , Willner JB et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer . Am J Obstet Gynecol 2005; 193: 662-667 .

114.

Albarghouthi MN , Barron AE. Polymeric matrices for DNA sequencing by capillary electrophoresis . Electrophoresis 2000; 21: 4096-4111 .

115.

Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies . Clin Chem 2001; 47: 164-172 .

116.

Schaefer KL , Wai D , Poremba C , Diallo R et al. Analysis of TP53 mutations in pediatric tumor patients using microarray-based sequencing technology . Med Pediatr Oncol 2002; 38: 247-253 .

117.

Drmanac R , Drmanac S , Chui G , Diaz R et al. Sequencing by hybridization (SBH): advantages, achievements, and opportunities . Adv Biochem Eng/Biotechnol 2002; 77: 75-101 .

118.

Gunderson KL , Huang XC , Morris MS , Lipshutz RJ et al. Mutation detection by ligation to complete n-mer DNA arrays . Genome Res 1998; 8: 1142-1153 .

119.

Wikman FP et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples . Clin Chem 2000; 46: 1555-1561 .

120.

Diamandis EP. Sequencing with microarray technology - a powerful new tool for molecular diagnostics . Clin Chem 2000; 46: 1523-1525 .

121.

Shumaker JM , Tollet JJ , Filbin KJ , Montague-Smith MP et al. APEX disease gene resequencing: mutations in exon 7 of the p53 tumor suppressor gene . Bioorgan Med Chem 2001; 9: 2269-2278 .

122.

Broude NE , Woodward K , Cavallo R , Cantor CR et al. DNA microarrays with stem-loop DNA probes: preparation and applications . Nucl Acid Res 2001; 29(19): E92-E92 .

123.

Huber M , Losert D , Hiller R , Harwanegg C et al. Detection of single base alterations in genomic DNA by solid phase polymerase chain reaction on oligonucleotide microarrays . Anal Biochem 2001; 299: 24-30 .

124.

Bosch FX , Ritter D , Enders C , Flechtenmacher C et al. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value . Int J Cancer 2004; 111: 530-538 .

125.

Ahrendt SA , Halachmi S , Chow JT , Wu L et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array . Proc Natl Acad Sci USA 1999; 96: 7382-7387 .

126.

Cooper M , Li SQ , Bhardwaj T , Rohan T , Kandel RA. Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens . Clin Chem 2004; 50: 500-508 .

127.

Hernandez-Boussard TM , Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database . Environ Health Perspect 1998; 106: 385-391 .